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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary 
liver cancer.1 It is the only malignancy of which the clinical practice 
for diagnosis is to use imaging without pathological confirmation 
in high-risk patients; thus, reliable noninvasive imaging criteria 
are crucial.2,3 To achieve consistent diagnosis of HCC, several sci-
entific organizations have proposed imaging-based diagnostic cri-
teria. The imaging criteria differ between geographic areas, reflecting 
differences in clinical environment and treatment strategies.4,5
The Liver Imaging Reporting and Data System (LI-RADS), en-
dorsed by the American College of Radiology, is a comprehensive 
system to standardize the terminology, technique, interpretation, 
reporting, and data collection of liver imaging in patients at risk 
for HCC.6 LI-RADS is currently the most widely used noninvasive 
diagnostic criteria for HCC in radiological studies because it pro-
vides detailed definitions for major and ancillary imaging features 
of HCCs. LI-RADS categorizes an observation according to its 
probability of HCC (ranging from LR-1 to LR-5) or malignancy but 
not specific for HCC (LR-M), on the basis of major, ancillary, and 
LR-M imaging features.6 LI-RADS 2018 represents the fourth up-
date and has been fully integrated into the American Association 
for the Study of Liver Disease 2018 HCC Practice Guidance.2 LI-
RADS was developed and modified predominantly based on data 
from Western countries and was designed to emphasize the speci-
ficity and positive predictive value over sensitivity for liver trans-
plant eligibility.4,5
The Korean Liver Cancer Study Group (KLCSG)-National Cancer 
Center (NCC) HCC practice guidelines were first announced in 
2003 and have been revised in 2009 and 2014.7-9 Since then, the 
Korean Liver Cancer Association (KLCA, formerly KLCSG)-NCC 
published KLCA-NCC 2018 practice guidelines for the manage-
ment of HCC.10 They provide diagnosis and treatment guideline 
specific to the Asian who manifest different clinical behaviors of 
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generalized estimating equation method.
Results: On ECA-MRI, the sensitivity and specificity of LI-RADS 2018 and KLCA-NCC 2018 were not significantly different 
(LR-5 vs. definite HCC: 75.8% vs. 69.4%, P=0.095 and 95.8% vs. 95.8%, P>0.999; LR-5/4 vs. definite/probable HCC: 87.1% 
vs.83.9%, P=0.313 and 87.5% vs. 91.7%, P=0.307). On HBA-MRI, definite HCC of KLCA-NCC 2018 showed significantly 
higher sensitivity (79.1% vs. 68.2%, P<0.001) than LR-5 of LI-RADS 2018 without a significant difference in specificity (93.9% 
vs. 95.4%, P=0.314). Definite/probable HCC of KLCA-NCC 2018 had higher specificity (92.3% vs. 80.0%, P=0.003) than LR-
5/4 of LI-RADS 2018. The sensitivity was lower for definite/probable HCC than for LR-5/4 without statistical significance 
(85.6% vs. 88.1%, P=0.057).
Conclusions: On ECA-MRI, LI-RADS 2018 and KLCA-NCC 2018 showed comparable diagnostic performances. On 
HBA-MRI, definite HCC of KLCA-NCC 2018 provided better sensitivity than LR-5 category of LI-RADS 2018 without 
compromising the specificity, while definite/probable HCC of KLCA-NCC 2018 revealed higher specificity than LR-5/4 of 
LI-RADS 2018 for diagnosing HCC. (Clin Mol Hepatol 2020;26:340-351)
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Study Highlights
This study compared the LI-RADS 2018 and KLCA-NCC 2018 criteria on magnetic resonance imaging (MRI) for the noninvasive diagnosis of hepato-
cellular carcinoma (HCC). On extracellular contrast agent (ECA)-MRI, LI-RADS 2018 and KLCA-NCC 2018 show comparable diagnostic performances. 
On hepatobiliary agent (HBA)-MRI, definite HCC of KLCA-NCC 2018 provides better sensitivity than LR-5 of LI-RADS 2018 without a significant differ-
ence in the specificity.
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HCC compared to Western population, especially in Korean.7-10 
The KLCA-NCC 2018 practice guidelines for the imaging diagnosis 
of HCC has been revised into a non-binary decision algorithm that 
covers the whole spectrum of observations, similar to LI-RADS.10 
The KLCA-NCC 2018 guidelines categorize an observation into in-
determinate, probable HCC, and definite HCC after excluding be-
nign lesions such as cyst or hemangiomas based on bright T2 signal 
intensity and other malignancies based on targetoid appear-
ance.10,11 KLCA-NCC 2018 was designed to favor high sensitivity 
for the detection of early HCC and early treatment with locore-
gional therapies.4,5
However, data to support these updated versions of the imag-
ing criteria are insufficient; moreover, limited data are available to 
compare the LI-RADS 2018 and KLCA-NCC 2018 criteria for the 
noninvasive diagnosis of HCC. Therefore, this study aimed to com-
pare the diagnostic performances of LI-RADS 2018 and KLCA-
NCC 2018 criteria on magnetic resonance imaging (MRI) for diag-
nosing HCC in high-risk patients.
MATERIALS AND METHODS 
This retrospective study was approved by the Institutional Re-
view Board of Severance Hospital (IRB number 4-2019-1127) and 
the requirement for informed consent was waived.
Patients
We searched our institution’s databases for a clinical cohort un-
der HCC surveillance and identified 2,576 patients who under-
went MRI for further diagnostic workup between January 2016 
and December 2017. The inclusion criteria were as follows: 1) age 
of 18 years or older; 2) patients at high risk for HCC with cirrhosis 
or chronic hepatitis B; 3) presence of at least one and up to five 
hepatic lesions (each ≥1 cm) on MRI; and 4) no previous treat-
ment for hepatic lesions. The exclusion criteria were as follows: 
1) patients with cirrhosis due to congenital hepatic fibrosis and 
vascular disorders such as hereditary hemorrhagic telangiectasia, 
Budd-Chiari syndrome, chronic portal vein occlusion, cardiac con-
gestion, or diffuse nodular regenerative hyperplasia (n=17); and 
2) patients with insufficient final diagnosis such as unknown final 
diagnosis of malignancy as a result of immediate locoregional 
therapy or insufficient follow-up (<2 years) for benign lesions to 
determine size stability (n=579). We did not include observations 
such as hepatic cysts, perfusion alteration, hepatic fat deposition 
or sparing, hypertrophic pseudomass, confluent fibrosis, and focal 
scar. However, we include hemangiomas in our study. A radiolo-
gist (S.K., with 9 years of experience in abdominal radiology) who 
was not involved in the image analysis for this study finalized the 
study population and selected hepatic lesions.
MRI examination
MRI was performed using 3.0-T systems (Magnetom Trio Tim, 
Siemens Healthineers, Erlangen, Germany; Intera Achieva, Inge-
nia, or Ingenia CX, Philips Healthcare, Best, the Netherlands; and 
Discovery MR 750w, GE Healthcare, Waukesha, WI, USA). The 
protocol included acquisition of dual-echo T1-weighted gradient-
echo images (in-phase and opposed-phase), T1-weighted 3-di-
mensional gradient-echo images with dynamic contrast enhance-
ment, navigator-triggered single- or multi-shot T2-weighted 
images, and diffusion-weighted images at b -values of 0 or 50, 
400, and 800 s/mm2. Dynamic T1-weighted imaging was per-
formed before and after administering one of the two extracellu-
lar contrast agents (ECAs) (gadoterate meglumine, Dotarem, 
Guerbet SA, Aulnay-sous-Bois, France; or gadobutrol, Gadovist, 
Bayer Pharma AG, Berlin, Germany) or a hepatobiliary agent (HBA) 
(gadoxetate disodium, Primovist, Bayer Pharma AG): a bolus in-
jection of 0.2 mL/kg of gadoterate meglumine (n=67) at a rate of 
2.0 mL/s or 0.1 mL/kg of gadobutrol (n=4) at a rate of 1.0 mL/s, 
or 0.1 mL/kg gadoxetate disodium (n=202) at a rate of 1.0 mL/s, 
followed by a 20-mL saline flush using a power injector. The 
choice of MRI contrast agents (ECA or HBA) was made at the dis-
cretion of the physicians. The physicians were fully informed by 
radiologists regarding the advantages and disadvantages of each 
contrast material at a multidisciplinary conference in our institu-
tion, such as the potential differences in terms of degree of arteri-
al phase (AP) enhancement and relative frequency of artifacts be-
tween the two contrast materials, potential benefits of hepatobiliary 
phase (HBP) images, and cost of contrast materials. AP scanning 
was initiated using the test-bolus or bolus-tracking technique. 
Thereafter, portal venous phase (PVP) and delayed phase (DP) im-
ages were obtained by ECA-MRI, while PVP, transitional phase 
(TP), and 20-minute HBP images were obtained by HBA-MRI. The 
detailed parameters of the MRI sequences are presented in Sup-
plementary Table 1.
Lesion registry
A radiologist (S.K., with 9 years of experience in abdominal ra-
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diology) who was not involved in the image analysis bookmarked 
individual lesions, reported the lesion size and location, and pro-
vided a list for further review. The prior computed tomography or 
MRI examination was used to assess threshold or subthreshold 
growth, and ultrasound (US) was used to assess US visibility as a 
discrete nodule when available.
Image analysis
Two board-certified abdominal radiologists (M.J.K. and S.L. 
with 27 and 8 years of experience in liver imaging, respectively) 
who did not participate in the patient and lesion selection re-
viewed all images. They were blinded to the final diagnosis of 
each lesion but were informed that the study population consisted 
of patients at high risk for HCC. Both LI-RADS 2018 and KLCA-
NCC 2018 criteria were independently applied to each lesion. Af-
ter independent categorization, the inter-reader agreement was 
evaluated. Discrepancies between the readers were resolved by 
consensus. Consensus data were used for the main image analysis 
results.
LI-RADS 2018
According to LI-RADS 2018, the readers reviewed the presence 
or absence of major, ancillary, and LR-M imaging features (Sup-
plementary Table 2).6 Each lesion was assigned to one of the fol-
lowing categories: LR-1 for definitely benign, LR-2 for probably 
benign, LR-3 for intermediate probability of malignancy, LR-4 for 
probably HCC, LR-5 for definitely HCC, LR-M for probably or defi-
nitely malignant but not specific for HCC, and LR-TIV for definite 
tumor in vein.6 The LI-RADS 2018 category could be adjusted by 
applying ancillary features and then tie-breaking rules, if needed.6
KLCA-NCC 2018
According to KLCA-NCC 2018, the readers assessed the pres-
ence or absence of major and ancillary imaging features and tar-
getoid appearance (Supplementary Table 3).10,11 Each lesion was 
categorized as definite HCC, probable HCC, indeterminate, be-
nign, and targetoid appearance. Definite HCC was defined as AP 
hyperenhancement with washout in the PVP, DP, or HBP.10,11 In a 
lesion with some but not all of the major imaging features of HCC, 
probable HCC was assigned only when the lesion fulfilled at least 
one item from each of the following two categories of ancillary 
imaging features: favoring malignancy in general, and favoring 
HCC in particular.10,11 The diagnostic criteria for HCC should be ap-
plied in a stepwise manner after excluding marked T2 hyperinten-
sity or targetoid appearance.10,11 When the imaging diagnosis was 
inconclusive, a lesion was defined as indeterminate.10,11 Although 
the KLCA-NCC 2018 guidelines do not clearly define benign and 
other malignancy categories, we added benign lesions and targe-
toid appearance to the system in order to match the classification 
with the LI-RADS 2018. A lesion that fulfilled at least one of the 
ancillary features favoring benignity according to KLCA-NCC 
201810,11 was classified as a benign lesion. Targetoid appearance 
was evaluated on diffusion-weighted imaging (DWI) or contrast-
enhanced sequences.
Comparison of LI-RADS 2018 and KLCA-NCC 2018
Definite HCC of KLCA-NCC 2018 corresponds to LR-5 of LI-
RADS 2018, and probable HCC of KLCA-NCC 2018 corresponds 
to LR-4 of LI-RADS 2018. For the noninvasive diagnosis of HCC, 
definite HCC of KLCA-NCC 2018 was compared with LR-5 of LI-
RADS 2018, and definite or probable HCC (definite/probable HCC) 
of KLCA-NCC 2018 was compared with LR-5 or LR-4 (LR-5/4) of 
LI-RADS 2018.
Reference standards
The diagnoses of HCCs and non-HCC malignancies were based 
on pathology including surgical resection (n=285) or explant for 
transplantation (n=15). Benign diagnoses were obtained by pa-
thology (n=14) or typical imaging features and stability at imaging 
for at least 2 years (n=38). The mean interval between the MRI 
and pathological diagnosis was 20.2 days (range, 0–90 days).
Statistical analysis
The baseline characteristics of patients and lesions were com-
pared between the ECA-MRI and HBA-MRI groups using the Fish-
er’s exact test for categorical variables and the two-sample t  test 
or Mann-Whitney U test for continuous variables. The per-lesion 
diagnostic performances of LI-RADS 2018 and KLCA-NCC 2018 
were compared by using the generalized estimating equation 
method. The inter-reader agreement was evaluated using the Co-
hen κ coefficient. The κ values were interpreted as follows: poor, 
0.00–0.20; fair, 0.21–0.40; moderate, 0.41–0.60; good, 0.61–
0.80; and excellent, 0.81–1.00. Statistical analyses were per-
formed using SAS software (version 9.4; SAS Inc., Cary, NC, USA). 
A P-value of <0.05 was considered statistically significant.
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RESULTS
Characteristics of patients and lesions 
A total of 273 patients (mean age, 57.3 years; 188 men and 85 
women) with 352 lesions were selected for the final statistical 
analysis (Fig. 1). The characteristics of the patients and lesions are 
presented in Table 1. The study consisted of 71 patients with 86 
lesions who underwent ECA-MRI, and 202 patients with 266 le-
sions who underwent HBA-MRI. No statistically significant differ-
ences in sex, age, presence of liver cirrhosis, lesion size, propor-
tions of categories according to LI-RADS 2018 and KLCA-NCC 
2018, and final diagnosis were found between ECA-MRI and 
HBA-MRI groups. Hepatitis B (89.8%) was the predominant etiol-
ogy of liver disease. Two hundred eighteen (79.9%) patients had 
one lesion; 37 (13.6%) had two lesions; and 18 (6.5%) had three 
or more lesions. The 352 lesions included 263 (74.7%) HCCs, 37 
(10.5%) non-HCC malignancies, and 52 (14.8%) benign lesions.
LR-5 of LI-RADS 2018 versus definite HCC of KLCA-
NCC 2018 
The per-lesion diagnostic performances for LR-5 of LI-RADS 
2018 and definite HCC of KLCA-NCC 2018 are demonstrated in 
Table 2.
On ECA-MRI, the sensitivity and specificity of LR-5 of LI-RADS 
2018 and definite HCC of KLCA-NCC 2018 were not significantly 
different (75.8% vs. 69.4%, P=0.095 and 95.8% vs. 95.8%, 
P>0.999) for the entire cohort. In both subgroups according to 
the size of lesions (10–19 mm and ≥20 mm), there were no sig-
nificantly differences in the sensitivities and specificities between 
LR-5 and definite HCC (all, P>0.05).
On HBA-MRI, the sensitivity was significantly higher for definite 
HCC of KLCA-NCC 2018 (79.1% vs. 68.2%, P<0.001) than for 
LR-5 of LI-RADS 2018 without a significant difference in specifici-
ty (93.9% vs. 95.4%, P=0.314) for all lesions. When lesions were 
stratified according to the size (10–19 mm and ≥20 mm), the 
sensitivities of definite HCC were significantly higher than those 
of LR-5 (10–19 mm: 75.8% vs. 51.6%, P<0.001; and ≥20 mm: 
80.6% vs. 75.5%, P=0.017), but the specificities were not signifi-
cantly different (all, P>0.05), similar to the results obtained for all 
lesions (Figs. 2, 3).
There were 27 lesions with threshold growth (24 HCCs and 
three non-HCC malignancies) according to LI-RADS 2018. By us-
ing only threshold growth (one of the major imaging features of 
LI-RADS 2018) with AP hyperenhancement, two additional HCCs 
were diagnosed as LR-5.
LR-5/4 of LI-RADS 2018 versus definite/probable HCC 
of KLCA-NCC 2018
The per-lesion diagnostic performances of LR-5/4 of LI-RADS 
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Table 1. Characteristics of 273 patients and 352 lesions
Characteristic Total ECA-MRI HBA-MRI P-value
Patients 273 71 202
Sex, male 188 (68.9) 46 (64.8) 142 (70.3) 0.456
Age (years)* 57.3±9.5 57.4±9.9 57.3±9.4 0.950
Etiology 0.022
Hepatitis B 245 (89.8) 60 (84.5) 185 (91.6)
Hepatitis C 11 (4.0) 7 (9.9) 4 (2.0)
Alcohol 17 (6.2) 4 (5.6) 13 (6.4)
Liver cirrhosis 150 (54.9) 39 (54.9) 111 (55.0) 0.998
Lesions 352 86 266
Size (mm)† 24 (15–34) 25 (19–32) 24 (15–35) 0.416
Size subgroup 0.307
10–19 mm 132 (37.5) 28 (32.6) 104 (39.1)
≥20 mm 220 (62.5) 58 (67.4) 162 (60.9)
Categorization according to LI-RADS 2018 0.111
LR-2 30 (8.5) 7 (8.1) 23 (8.7)
LR-3 14 (4.0) 7 (8.1) 7 (2.6)
LR-4 59 (16.8) 9 (10.5) 50 (18.8)
LR-5 188 (53.4) 48 (55.8) 140 (52.6)
LR-M 59 (16.8) 14 (16.3) 45 (16.9)
LR-TIV 2 (0.5) 1 (1.2) 1 (0.4)
Categorization according to KLCA-NCC 2018 0.135
Benign 31 (8.8) 11 (12.8) 20 (7.5)
Indeterminate 31 (8.8) 7 (8.1) 24 (9.0)
Probable HCC 24 (6.8) 10 (11.6) 14 (5.3)
Definite HCC 207 (58.8) 44 (51.2) 163 (61.3)
Targetoid appearance 59 (16.8) 14 (16.3) 45 (16.9)
Final diagnosis 0.051
HCC 263 (74.7) 62 (72.1) 201 (75.6)
Non-HCC malignancy 37 (10.5) 9 (10.5) 28 (10.5)
cHCC-CCA 23 (6.6) 5 (5.8) 18 (6.8)
Intrahepatic cholangiocarcinoma 9 (2.5) 3 (3.5) 6 (2.2)
Hepatoblastoma 1 (0.3) 1 (1.2) 0 (0.0)
Metastasis 4 (1.1) 0 (0.0) 4 (1.5)
Benign lesion 52 (14.8) 15 (17.4) 37 (13.9)
Hemangioma 14 (4.0) 4 (4.6) 10 (3.8)
Focal nodular hyperplasia-like nodule 8 (2.3) 6 (7.0) 2 (0.7)
Regenerative nodule 17 (4.8) 3 (3.5) 14 (5.3)
Dysplastic nodule 13 (3.7) 2 (2.3) 11 (4.1)
Values are presented as mean±standard deviation, median (interquartile), or number (%).
ECA, extracellular contrast agent; MRI, magnetic resonance imaging; HBA, hepatobiliary agent; LI-RADS, Liver Imaging Reporting and Data System; KLCA, 
Korean Liver Cancer Association; HCC, hepatocellular carcinoma; cHCC-CCA, combined hepatocellular carcinoma-cholangiocarcinoma.
*Compared by using the two-sample t  test.
†Compared by using Mann-Whitney U test.
346 http://www.e-cmh.orghttps://doi.org/10.3350/cmh.2020.0004
Volume_26  Number_3  July 2020
2018 and definite/probable HCC of KLCA-NCC 2018 are summa-
rized in Table 3.
On ECA-MRI, no significant differences in the sensitivity and 
specificity were observed between LR-5/4 of LI-RADS 2018 and 
definite/probable HCC of KLCA-NCC 2018 (87.1% vs. 83.9%, 
P=0.313 and 87.5% vs. 91.7%, P=0.307) for the entire cohort. 
When lesions were stratified according to the size (10–19 mm and 
≥20 mm), the sensitivities and specificities of LR-5/4 and definite/
probable HCC were not significantly different for both subgroups 
(all, P>0.05).
On HBA-MRI, definite/probable HCC of KLCA-NCC 2018 
showed significantly higher specificity (92.3% vs. 80.0%, 
P=0.003) than LR-5/4 of LI-RADS 2018 for diagnosing HCC with-
out a statistically significant difference in sensitivity (85.6% vs. 
88.1%, P=0.057) for all lesions. The specificity of definite/proba-
ble HCC for 10–19 mm-sized lesions was significantly higher than 
that of LR-5/4 (92.9% vs. 73.8%, P=0.002), but the sensitivities 
for 10–19 mm-sized lesions and ≥20 mm-sized lesions were not 
significantly different (all, P>0.05).
False-positive diagnoses for HCC
There were four false-positive diagnoses in LR-5 of LI-RADS 
2018 and five false-positive diagnoses in definite HCC of KLCA-
NCC 2018. All false-positive results were combined hepatocellular 
carcinoma-cholangiocarcinoma (cHCC-CCA) (Fig. 4, Supplementary 
Table 4).
In LR-5/4 of LI-RADS 2018, the false-positive results were eight 
non-HCC malignancies (six HCC-CCAs, one hepatoblastoma, and 
one metastasis) and eight benign lesions (two focal nodular hy-
perplasia-like nodules and six dysplastic nodules). In definite/
probable HCC of KLCA-NCC 2018, the false-positive diagnoses 
were six cHCC-CCAs and one hepatoblastoma (Supplementary 
Table 5).
Subgroup analysis in patients with hepatitis B
Supplementary Table 6 and 7 present the subgroup analysis re-
sults in patients with hepatitis B. The results of patients with hep-
Table 2. Diagnostic performances of LR-5 of LI-RADS 2018 and definite HCC of KLCA-NCC 2018 for diagnosing HCC on ECA-MRI and HBA-MRI
LR-5 of LI-RADS 2018  
(95% CI)




Sensitivity 75.8 (65.2–86.5) 69.4 (57.9–80.8) 0.095 
Specificity 95.8 (87.8–100.0) 95.8 (87.8–100.0) >0.999
ECA-MRI 10–19 mm (n=28)
Sensitivity 58.8 (35.4–82.2) 58.8 (35.4–82.2) >0.999
Specificity 100.0 (100.0–100.0) 100.0 (100.0–100.0) >0.999
ECA-MRI ≥20 mm (n=58)
Sensitivity 82.2 (71.1–93.4) 73.3 (60.4–86.3) 0.092 
Specificity 92.3 (77.8–100.0) 92.3 (77.8–100.0) 0.109 
HBA-MRI all (n=266)
Sensitivity 68.2 (61.7–74.6) 79.1 (73.5–84.7) <0.001
Specificity 95.4 (90.3–100.0) 93.9 (88.0–99.7) 0.314 
HBA-MRI 10–19 mm (n=104)
Sensitivity 51.6 (39.2–64.1) 75.8 (65.2–86.5) <0.001
Specificity 97.6 (93.0–100.0) 95.2 (88.8–100.0) 0.312 
HBA-MRI ≥20 mm (n=162)
Sensitivity 75.5 (68.4–82.7) 80.6 (74.0–87.2) 0.017 
Specificity 91.3 (79.8–100.0) 91.3 (79.8–100.0) >0.999
LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; ECA, 
extracellular contrast agent; MRI, magnetic resonance imaging; HBA, hepatobiliary agent; CI, confidence interval.
*P-values between LR-5 of LI-RADS 2018 and definite HCC of KLCA-NCC 2018 by using the generalized estimating equation method.
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atitis B were similar and in line with those of the entire cohort.
On ECA-MRI, the sensitivity and specificity of LI-RADS 2018 
and KLCA-NCC 2018 were not significantly different (LR-5 vs. def-
inite HCC: 75.0% vs. 67.9%, P=0.094 and 93.3% vs. 93.3%, 
P >0.999; LR-5/4 vs. definite/probable HCC: 87.5% vs. 83.9%, 
P=0.313 and 86.7% vs. 86.7%, P>0.999).
On HBA-MRI, definite HCC of KLCA-NCC 2018 showed signifi-
cantly higher sensitivity (79.1% vs. 68.5%, P<0.001) than LR-5 of 
LI-RADS 2018 without a significant difference in specificity 
(94.9% vs. 96.6%, P=0.313). Definite/probable HCC of KLCA-
NCC 2018 had higher specificity (93.2% vs. 81.4%, P=0.005) 
than LR-5/4 of LI-RADS 2018. The sensitivity was lower for defi-
nite/probable HCC than for LR-5/4 without statistical significance 
(85.0% vs. 87.7%, P=0.056).
Inter-reader agreement
The inter-reader agreement for the categorization of lesions ac-
Figure 2. HCC in a 53-year-old man with chronic hepatitis B. On the arterial (A), portal venous (B), and hepatobiliary phase (C) images, after administra-
tion of hepatobiliary agent, a 39-mm liver mass (arrows) showed arterial phase hyperenhancement without washout in the portal venous phase, while 
showing hypointensity in the hepatobiliary phase. The mass was categorized as LR-4 by LI-RADS 2018, but classified as definite HCC by KLCA-NCC 
2018. HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting and Data System; KLCA-NCC, Korean Liver Cancer Association-National Cancer 
Center.
A B C
Figure 3. HCC in a 60-year-old woman with cirrhosis related to hepatitis B. On the arterial (A), portal venous (B), and hepatobiliary phase (C) images af-
ter administration of hepatobiliary agent, a 36-mm liver mass (arrows) showed arterial phase hyperenhancement without washout but with enhanc-
ing capsule in the portal venous phase, and hyperintensity in the hepatobiliary phase. On T2-weighted image (D), the mass demonstrated mild-mod-
erate T2 hyperintensity. The mass was categorized as LR-5 by LI-RAD 2018, but classified as probable HCC by KLCA-NCC 2018. HCC, hepatocellular 
carcinoma; LI-RADS, Liver Imaging Reporting and Data System; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center.
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Table 3. Diagnostic performances of LR-5/4 of LI-RADS 2018 and definite/probable HCC of KLCA-NCC 2018 for diagnosing HCC on ECA-MRI and HBA-
MRI
LR-5/4 of LI-RADS 2018  
(95% CI)
Definite/probable HCC of  
KLCA-NCC 2018 (95% CI)
P-value*
ECA-MRI all (n=86)
Sensitivity 87.1 (78.8–95.4) 83.9 (74.7–93.0) 0.313 
Specificity 87.5 (74.3–100.0) 91.7 (80.6–100.0) 0.307 
ECA-MRI 10–19 mm (n=28)
Sensitivity 94.1 (82.9–100.0) 76.5 (56.3–96.6) 0.056 
Specificity 100.0 (100.0–100.0) 100.0 (100.0–100.0) >0.999
ECA-MRI ≥20 mm (n=58)
Sensitivity 84.4 (73.9–95.0) 86.7 (76.7–96.6) 0.312 
Specificity 76.9 (54.0–99.8) 84.6 (65.0–100.0) 0.298 
HBA-MRI all (n=266)
Sensitivity 88.1 (83.6–92.5) 85.6 (80.7–90.4) 0.057 
Specificity 80.0 (70.3–89.7) 92.3 (85.8–98.8) 0.003 
HBA-MRI 10–19 mm (n=104)
Sensitivity 87.1 (78.8–95.4) 82.3 (72.8–91.8) 0.076 
Specificity 73.8 (60.5–87.1) 92.9 (85.1–100.0) 0.002 
HBA-MRI ≥20 mm (n=162)
Sensitivity 88.5 (83.2–93.8) 87.1 (81.5–92.6) 0.316 
Specificity 91.3 (79.8–100.0) 91.3 (79.8–100.0) >0.999
LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; ECA, 
extracellular contrast agent; MRI, magnetic resonance imaging; HBA, hepatobiliary agent; CI, confidence interval.
*P-values between LR-5/4 of LI-RADS 2018 and definite/probable HCC of KLCA-NCC 2018 by using the generalized estimating equation method.
Figure 4. cHCC-CCA in a 62-year-old man with chronic hepatitis B. On the arterial (A), portal venous (B), and delayed phase (C) images, after adminis-
tration of extracellular contrast agent, a 26-mm liver mass (arrows) showed arterial phase hyperenhancement with washout and enhancing capsule in 
the portal venous and delayed phases. The mass was categorized as LR-5 by LI-RADS 2018, and classified as definite HCC by KLCA-NCC 2018. However, 
it was diagnosed as cHCC-CCA by surgical resection. cHCC-CCA, combined hepatocellular carcinoma-cholangiocarcinoma; LI-RADS, Liver Imaging Re-
porting and Data System; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center.
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cording to LI-RADS 2018 and KLCA-NCC 2018 was excellent 
(κ=0.90–0.97). The detailed results of inter-reader agreement are 
provided in Supplementary Table 8.
DISCUSSION
Our study showed that LI-RADS 2018 and KLCA-NCC 2018 had 
comparable diagnostic performances on ECA-MRI. On HBA-MRI, 
definite HCC of KLCA-NCC 2018 showed better sensitivity with-
out a significant change in specificity, compared to LR-5 of LI-
RADS 2018. Definite/probable HCC of KLCA-NCC 2018 provided 
higher specificity than LR-5/4 of LI-RADS 2018 when using HBA-
MRI.
Our study indicates that KLCA-NCC 2018 may provide better di-
agnostic performance than LI-RADS 2018 to diagnose HCC with 
HBA-MRI, but not with ECA-MRI. The discrepancy may be attrib-
uted to the different definitions of washout appearance between 
the two systems. LI-RADS 2018 states that washout should be 
determined in the PVP only for HBA-MRI,6 whereas KLCA-NCC 
2018 defines washout not only in the PVP but also in the TP or 
HBP.10,11 In our study, on HBA-MRI, the use of washout appear-
ance defined by KLCA-NCC 2018 enabled the diagnosis of 23 ad-
ditional HCC lesions compared to that defined by LI-RADS 2018, 
which resulted in increased sensitivity for definite HCC of KLCA-
NCC 2018. This result is consistent with the results of recent stud-
ies that reported improved sensitivity by using HBP hypointensity 
as an alternative to washout on HBA-MRI.12-14 Nevertheless, defi-
nite HCC of KLCA-NCC 2018 did not significantly reduce its speci-
ficity compared with LR-5 of LI-RADS 2018. The diagnostic criteria 
for HCC according to KLCA-NCC 2018 may prevent significant loss 
in specificity by excluding hemangiomas or other malignancies, 
based on ancillary features favoring benignity such as marked T2 
hyperintensity or targetoid appearance on DWI or contrast-en-
hanced sequences prior to the application of major imaging fea-
tures. The use of a sequential algorithm with stepwise consider-
ation in KLCA-NCC 2018 as in LI-RADS 2018 seems to help 
maintain a high specificity for the diagnosis of HCC.5,10,11,15,16
LI-RADS 2018 and KLCA-NCC 2018 are unique compared to 
other noninvasive imaging criteria in that they adapt non-binary 
decision algorithms and incorporate ancillary imaging features to 
modulate the likelihood of HCC. They allow categories for proba-
bly HCC (designated as LR-4 of LI-RADS 2018 and probable HCC 
of KLCA-NCC 2018) with different combinations of major and an-
cillary imaging features. Observations that do not meet stringent 
LR-5 criteria of LI-RADS or lesions with some but not all of the 
major imaging features of KLCA-NCC 2018 criteria can be appro-
priately categorized as LR-4 of LI-RADS 2018 or probable HCC of 
KLCA-NCC 2018. While an observation can be upgraded from 
LR-3 to LR-4 with any of the ancillary features favoring malignan-
cy in LI-RADS 2018, a lesion classified as probable HCC in KLCA-
NCC 2018 criteria requires at least one item from each of the two 
categories of ancillary imaging features (favoring malignancy in 
general and favoring HCC in particular). This difference may con-
tribute to a statistically no significant difference in sensitivity but 
significantly higher specificity in definite/probable HCC of KLCA-
NCC 2018 as compared with LR-5/4 of LI-RADS 2018. In the pres-
ent study, LR-5/4 resulted in an unacceptably low specificity, 
which is consistent with some recent studies and a recent meta-
analysis.17-19 Meanwhile, definite/probable HCC of KLCA-NCC 
2018 maintained high specificity (>90%). In definite/probable 
HCC of KLCA-NCC 2018, false positive results were mostly due to 
cHCC-CCA, defined as primary liver carcinoma with both hepato-
cytic and cholangiocytic differentiation.20 Several studies have 
also reported that some cHCC-CCAs might not be distinguishable 
from HCCs based on imaging features.21,22
Our study has strength by comparing the diagnostic systems for 
the noninvasive diagnosis of HCC and identifying proper imaging 
criteria according to MRI contrast agents. This study indicates that 
KLCA-NCC 2018 may be more appropriate diagnostic criteria for 
HCC when using HBA-MRI. A recent prospective study comparing 
ECA-MRI and HBA-MRI intraindividually for the diagnosis of HCC 
has shown that the current LR-5 criteria of LI-RADS limited the 
sensitivity on HBA-MRI.23 In our study, LR-5 of LI-RADS 2018 also 
revealed suboptimal sensitivity on HBA-MRI, whereas definite 
HCC of KLCA-NCC 2018 showed higher sensitivity when using 
HBA-MRI. In particular, there was a greater difference in the sen-
sitivities of <10–19 mm lesions on HBA-MRI between LI-RADS 
and the KLCA-NCC 2018 guidelines. The diagnostic criteria for 
HCC need to be adjusted according to MRI contrast agent. In ad-
dition, imaging criteria reflect geographic differences in clinical 
environment and treatment strategies. In Korea, early treatment 
with locoregional therapies is widely used for HCC, thus, the use 
of KLCA-NCC 2018 diagnostic criteria may provide better sensitiv-
ity without compromise in specificity and help detection and early 
diagnosis of small HCC when using HBA-MRI.5
This study has several limitations. First, the retrospective study 
design at a single center may have introduced an inevitable selec-
tion bias. Second, the predominance of patients with chronic hep-
atitis B in our study population may limit the generalizability of 
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the results to other geographic populations with different etiolo-
gies of HCC. Additional prospective multicenter studies that in-
clude patients with various etiologies of liver disease are required 
to validate our results. Third, we used the reference standard for 
the final diagnosis of benign lesion not based on a pathological 
diagnosis alone but on a composite clinical reference standard. 
However, pathologic confirmation for highly suspected benign le-
sions is not recommended in clinical practice, and application of a 
strict standard of reference (only pathology) for benign lesions 
may have resulted in a confirmation bias. Finally, the blinded 
readers had participated in imaging diagnoses in their daily prac-
tice; thus, recall bias might have occurred.
In conclusion, LI-RADS 2018 and KLCA-NCC 2018 show compa-
rable diagnostic performances on ECA-MRI. On HBA-MRI, definite 
HCC of KLCA-NCC 2018 provides better sensitivity and accuracy 
than LR-5 category of LI-RADS 2018 and definite/probable HCC 
of KLCA-NCC 2018 reveals higher specificity than LR-5/4 of LI-
RADS 2018 for the noninvasive diagnosis of HCC.
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